New Research Shows Specific Garlic Varieties May Have Antiviral Properties, Products to Debut at Gilroy Garlic Festival

The Gilroy Garlic Festival, the nation's premier summer food event, will serve as the launchpad for new garlic products from SupaG Health Pty Ltd, founded by Nick Diamantopoulos. The introduction follows peer-reviewed studies published in scientific journals showing that specific garlic varieties likely possess significant antiviral properties. The research, published in the Journal of Functional Foods (2024) and JSFA Reports (2026), demonstrated that certain garlic extracts exhibited strong activity in laboratory studies against respiratory viruses including SARS-CoV-2 (COVID-19) and Influenza A. Notably, the antiviral activity was found to be cultivar-specific, meaning only a small subset of garlic varieties, regardless of growing location, showed meaningful effects.

"These findings fundamentally change the way we should think about garlic," said Diamantopoulos. "For generations, garlic has been viewed as a natural remedy however our research indicates that not all garlic is equal for health benefits, just as not all garlic is equal for nutrition and flavor." The research program draws on more than 30 years of collection, breeding, and analysis, involving over 300 garlic varieties sourced from around the world. Diamantopoulos believes the discoveries may represent one of the most historically significant scientific developments in the garlic industry.

The implications for Texas and beyond are substantial. As the nutraceutical and functional food sectors continue to grow, the ability to target specific health benefits with scientifically validated garlic cultivars opens new market opportunities. "The future of garlic nutraceuticals will not be commodity-based. It will be health-specific," Diamantopoulos explained. "We are moving from generic garlic products towards identified cultivars with targeted functional properties, proprietary formulations, traceable genetics and evidence-based health positioning."

SupaG Health is actively pursuing distribution partnerships, nutraceutical and pharmaceutical collaborations, and retail expansion opportunities. The company's proprietary ingredient is a premium garlic supplement supported by the peer-reviewed research. According to the published studies, biological activity likely depends on the underlying garlic cultivar, extraction methods, formulation techniques, and processing controls, creating opportunities to develop intellectual property around identified cultivars and proprietary formulations for the nutraceutical, functional food, and pharma sectors.

Throughout the festival, Diamantopoulos and the SupaGarlic team will be available to discuss the published research, commercial development plans, and opportunities for strategic partnerships, distribution, and clinical research partners. "This research establishes a scientific foundation for a new premium category within the health industry. Gilroy is the ideal place to begin that conversation with the world," Diamantopoulos said.

It is important to note that the scientific studies referenced were conducted in laboratory settings and do not constitute clinical evidence in humans. These statements have not been evaluated by the U.S. Food and Drug Administration, and SupaG Health products are not intended to diagnose, treat, cure, or prevent any disease.